New Insulins: Benefits and Challenges

Insulin degludec seemed to demonstrate a reduction in episodes of hypoglycemia, especially nocturnal hypoglycemia, by approximately 25% compared with insulin glargine, the FDA in its assessment highlighted the fact that this benefit was not a consistent feature seen across the different types of diabetes or definitions of hypoglycemia, in particular the more objective definitions of hypoglycemia .B enefits include flexibility of timing of insulin administration, the lack of weight gain or even weight loss, and some improvement in quality-of-life aspects.

 

 

 

 

<div style="&quot;text-align:" justify;"="">

 

 

 

 

 

 

 

 

 

    Related Conference of New Insulins: Benefits and Challenges

    April 10-11, 2025

    5th World Congress on Endocrine and Diabetes

    Dubai, UAE
    April 10-11, 2025

    4th International Summit on Hormonal Disorders

    Dubai, UAE
    May 08-09, 2025

    5th European Endocrinology and Diabetes Congress

    Madrid, Spain
    May 19-20, 2025

    6th World Summit on Diabetes

    Rome, Italy
    June 04-05, 2025

    4th World Congress on Diabetes and Pediatric Endocrinology

    Edinburgh, Scotland
    July 29-30, 2025

    15th World Congress on Endocrinology and Diabetes

    Paris, France
    September 08-09, 2025

    3rd World congress and Expo on Diabetes

    Frankfurt, Germany
    October 30-31, 2025

    5th Annual Summit on Diabetes and Endocrinology

    Paris, France
    November 06-07, 2025

    8th Annual Meeting on Diabetes and Endocrinology

    Dubai, UAE
    November 20-21, 2025

    21st World Congress on Endocrinology & Diabetes

    Paris, France

    New Insulins: Benefits and Challenges Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in